Onoact, discovered and developed internally by ONO, is a short-acting selective β 1 blocker which relaxes the tension of sympathetic nervous by selectively blocking β 1 receptor existing …
A Short-Acting Selective β1 Blocker, Onoact® for Intravenous …
2022年8月24日 · Onoact is a short-acting selective β 1 blocker that reduces heart rate by selectively blocking β 1 receptor which is present predominantly in the heart. Therefore, …
快速心律失常新药！小野制药在日本提交ONOACT新适应症申请： …
onoact是一种短效选择性β1受体阻滞剂，通过选择性阻断主要存在于心脏中的β1受体来降低心率。 ONOACT已被批准用于处置低心功能成人患者的快速心律 ...
Landiolol - Wikipedia
Landiolol, sold under the brand name Onoact among others, is a medication used for the treatment of tachycardia, atrial fibrillation, and atrial flutter. [1] [4] It is a beta-adrenergic …
Landiolol: a review of its use in intraoperative and postoperative ...
Landiolol (Onoact(®)) is an intravenously administered, ultra short-acting β1-blocker with an elimination half-life of 3-4 min and ≈8-fold greater cardioselectivity than esmolol in vitro. It is …
ONOACT is a short-acting selective β 1 blocker discovered and developed internally by ONO, which relaxes the tension of sympathetic nervous by selectively blocking β 1 receptors existing …
Landiolol Hydrochloride
Onoact ® is available as lyophilized injection powder for solution for intravenous use, containing 50 mg of Landiolol hydrochloride every vial. The recommended dose is intravenously …
小野制药宣布已在日本提交ONOACT新适应症申请，用于低心功能 …
2021年10月31日 · onoact是一种短效选择性β1受体阻滞剂，通过选择性阻断主要存在于心脏中的β1受体来降低心率。 ONOACT已被批准用于处置低心功能成人患者的快速心律失常。
support of the registration of Onoact 50 for injection in Japan and in the post-licensing phase of the product. The key clinical studies of Onoact have been published and are available in the …
新药Onoact（landiolol）在日本获批上市，治疗左心室（LV）功能 …
2023年1月30日 · 新药Onoact（landiolol hydrochloride，盐酸兰地洛尔）静脉输注是一种短效选择性β1受体阻滞剂，已被批准用于成人患者，紧急处置快速心律失常。 2013年2月19日，Ono …